TG Therapeutics, Inc. (NASDAQ:TGTX) Files An 8-K Other EventsItem 8.01. Other Events.
On October 11, 2018, TG Therapeutics, Inc. (“TG” or the “Company”) issued a press release in which it announced final results from its Phase 2 multicenter trial of ublituximab (TG-1101), the Company’s novel glycoengineered anti-CD20 monoclonal antibody, in relapsing forms of Multiple Sclerosis (RMS). The data was presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). A copy of the press release is being filed as Exhibit 99.1 and incorporated in this Item by reference.
Item 9.01 Financial Statements And Exhibits.
(d) Exhibits.
99.1 Press Release, dated October 11, 2018.
TG THERAPEUTICS, INC. ExhibitEX-99.1 2 v101518_ex991.htm EXHIBIT 99.1 Untitled Document TG Therapeutics,…To view the full exhibit click here
About TG Therapeutics, Inc. (NASDAQ:TGTX)
TG Therapeutics, Inc. (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for b-cell malignancies and autoimmune diseases. The Company is developing over two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the CD20 antigen found on mature B-lymphocytes. The Company is also developing TGR-1202, an orally available Phosphoinositide 3-kinase (PI3K) delta inhibitor. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies. The Company also has pre-clinical programs focusing on developing interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors and anti-PD-L1 and anti-GITR antibodies. The Company also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition and investment opportunities.
